Fibroblast Activation Protein

LONDON and PHILADELPHIA — September 16, 2026 Avacta Therapeutics announced clinical proof of mechanism for AVA6103, its next-generation controlled-release...

BOTHELL, Wash., July 20, 2026 Immunome, Inc. (Nasdaq: IMNM) announced that the first patient has been dosed in the...

BOSTON, May 29, 2026 Ratio Therapeutics has expanded its manufacturing collaboration with PharmaLogic Holdings Corp. to support the clinical...

DULLES, Va., Feb. 11, 2026 — SOFIE Biosciences announced that the first patient has been dosed in its Phase...